Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Acute Liver Failure Medication

  • Author: Gagan K Sood, MD; Chief Editor: BS Anand, MD  more...
 
Updated: Feb 04, 2016
 

Medication Summary

Multiple medications may be necessary in patients with acute liver failure because of the wide variety of complications that may develop from fulminant hepatic failure. Decreased hepatic metabolism and the potential for hepatotoxicity become central issues. In patients with liver failure from Amanita phalloides or acetaminophen toxicity, antidotes that effectively bind or eliminate the relevant toxins are essential.

Next

Antidotes

Class Summary

Antidotes neutralize toxic agents and neutralize or counteract any form of poisoning.

Penicillin G (Pfizerpen)

 

Intravenous penicillin G is the drug of choice for the treatment of mushroom poisoning from Amanita phalloides. Its mode of action is unclear in this setting.

Silibinin (Silibinin Plus)

 

Silibinin is a water-soluble derivative of silymarin, which is the active ingredient in the herbal preparation milk thistle. This agent possesses antioxidant properties that may benefit liver disease management.

Activated charcoal (Actidose-Aqua, Liqui-Char, CharcoAid)

 

In patients who have recently ingested A phalloides, activated charcoal may bind the toxin and prevent absorption.

N-acetylcysteine (Mucomyst, Mucosil)

 

N-acetylcysteine is the drug of choice in acetaminophen overdose. N-acetylcysteine provides reducing equivalents to help restore depleted intrahepatic glutathione levels.

Previous
Next

Osmotic Diuretic

Class Summary

Intracranial hypertension in acute liver failure is managed initially by the use of osmotic diuretics such as mannitol.

Mannitol (Osmitrol)

 

Osmotic diuresis with intravenous mannitol is effective in the short term for decreasing cerebral edema. Administration of intravenous mannitol (in a bolus dose of 0.5-1 g/kg or 50-100 g) is recommended to treat intracranial hypertension in acute liver failure. The dose may be repeated once or twice, as needed, provided that serum osmolality has not exceeded 320 mOsm/L. Volume overload is a risk with mannitol use in patients with renal impairment and may necessitate the use of dialysis to remove excess fluid.

Previous
Next

Barbiturate Agents

Class Summary

Barbiturate agents such as thiopental and pentobarbital may be considered when severe intracranial hypertension does not respond to other measures. Administration has been shown to effectively decrease intracranial pressure (ICP). Significant systemic hypotension frequently limits their use and may necessitate additional measures to maintain adequate mean arterial pressure.

Pentobarbital (Nembutal)

 

Pentobarbital is a short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. It may be used at high dosages to induce barbiturate coma for the treatment of refractory increased ICP. The recommended dose is 3-5 mg/kg intravenously as a loading dose, followed by infusion at 1-3 mg/kg/h intravenously.

Thiopental (Pentothal)

 

Thiopental is an ultra–short-acting central nervous system depressant that decreases intracranial pressure. The recommended dose of thiopental for intracranial hypertension is 5-10 mg/kg as a loading dose, followed by an infusion of 3-5 mg/kg intravenously.

Previous
Next

Benzodiazepine

Class Summary

As patients with fulminant hepatic failure drift deeper into coma, the ability to protect their airway from aspiration decreases. Short-acting benzodiazepines in low doses may be used before intubation.

Midazolam

 

Midazolam is a shorter-acting benzodiazepine sedative-hypnotic useful in patients requiring acute and/or short-term sedation. Midazolam is used for sedation for mechanically ventilated patients. It is given through continuous intravenous infusion for sedation of intubated and mechanically ventilated patients.

Previous
Next

Anesthetic Agents

Class Summary

Anesthetic agents such as propofol have sedative and hypnotic effects that are used for induction.

Propofol (Diprivan)

 

Propofol is a sedative-hypnotic that decreases the cerebral blood flow and intracranial hypertension. Propofol (50 mcg/kg/min) may be initiated before intubation and continued as an infusion.

Previous
 
Contributor Information and Disclosures
Author

Gagan K Sood, MD Associate Professor, Department of Medicine and Surgery, Baylor College of Medicine

Gagan K Sood, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association

Disclosure: Nothing to disclose.

Coauthor(s)

Mark S Slabinski, MD, FACEP, FAAEM Vice President, EMP Medical Group

Mark S Slabinski, MD, FACEP, FAAEM is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Ohio State Medical Association

Disclosure: Nothing to disclose.

Steven A Conrad, MD, PhD Chief, Department of Emergency Medicine; Chief, Multidisciplinary Critical Care Service, Professor, Department of Emergency and Internal Medicine, Louisiana State University Health Sciences Center

Steven A Conrad, MD, PhD is a member of the following medical societies: American College of Chest Physicians, American College of Critical Care Medicine, American College of Emergency Physicians, American College of Physicians, International Society for Heart and Lung Transplantation, Louisiana State Medical Society, Shock Society, Society for Academic Emergency Medicine, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Lemi Luu, MD, RDMS, FACEP, FAAEM Attending Physician, Department of Emergency Medicine, Bridgeport Hospital, Yale-New Haven Health System

Lemi Luu, MD, RDMS, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Institute of Ultrasound in Medicine

Disclosure: Nothing to disclose.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Acknowledgements

David Eric Bernstein, MD Director of Hepatology, North Shore University Hospital; Professor of Clinical Medicine, Albert Einstein College of Medicine

David Eric Bernstein, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Oscar S Brann, MD, FACP Associate Clinical Professor, Department of Medicine, University of California at San Diego; Consulting Staff, Mecklenburg Medical Group

Oscar S Brann, MD, FACP is a member of the following medical societies: American Gastroenterological Association

Disclosure: Nothing to disclose.

Blake A Jones, MD New Hampshire Gastroenterology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Carin M Van Gelder, MD Assistant Professor, Department of Emergency Medicine, Yale University; EMS Medical Director, NHSHP and EMS Physician, SHARP Team; Attending Physician, Emergency Medicine, Yale-New Haven Medical Center

Carin M Van Gelder, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Massachusetts Medical Society, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

References
  1. [Guideline] Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005 May. 41(5):1179-97. [Medline].

  2. Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007 Nov. 35(11):2498-508. [Medline].

  3. Bernal W. Intensive care support therapy. Liver Transpl. 2003 Sep. 9(9):S15-7. [Medline].

  4. Jalan R. Acute liver failure: current management and future prospects. J Hepatol. 2005. 42 Suppl(1):S115-23. [Medline].

  5. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs. 1994 May. 18(5):390-6. [Medline].

  6. Hughes RD, Williams R. Use of bioartificial and artificial liver support devices. Semin Liver Dis. 1996 Nov. 16(4):435-44. [Medline].

  7. Nyberg SL, Misra SP. Hepatocyte liver-assist systems--a clinical update. Mayo Clin Proc. 1998 Aug. 73(8):765-71. [Medline].

  8. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004 May. 239(5):660-7; discussion 667-70. [Medline]. [Full Text].

  9. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology. 2004 Nov. 127(5):1338-46. [Medline].

  10. Jiang W, Desjardins P, Butterworth RF. Hypothermia attenuates oxidative/nitrosative stress, encephalopathy and brain edema in acute (ischemic) liver failure. Neurochem Int. 2009 Jul-Aug. 55(1-3):124-8. [Medline].

  11. Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995 Jan. 21(1):240-52. [Medline].

  12. Lee WM, Schiodt FV. Fulminant hepatic failure. In: Schiff ER, Sorrell, MF, Maddrey WC, eds. Schiff's Diseases of the Liver. 8th ed. Baltimore: Md: Lippincott Williams & Wilkins; 1999.

  13. Lidofsky SD, Bass NM, Prager MC, Washington DE, Read AE, Wright TL, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology. 1992 Jul. 16(1):1-7. [Medline].

  14. Detry O, Arkadopoulos N, Ting P, Kahaku E, Margulies J, Arnaout W, et al. Intracranial pressure during liver transplantation for fulminant hepatic failure. Transplantation. 1999 Mar 15. 67(5):767-70. [Medline].

  15. Schiødt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med. 1997 Oct 16. 337(16):1112-7. [Medline].

  16. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005 Dec. 42(6):1364-72. [Medline].

  17. Davern TJ 2nd, James LP, Hinson JA, Polson J, Larson AM, Fontana RJ, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology. 2006 Mar. 130(3):687-94. [Medline].

  18. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011 Feb. 53(2):567-76. [Medline].

  19. Paterson JM, Mamdani MM, Manno M, Juurlink DN. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012 Aug 13. [Medline].

  20. Notes from the field: acute hepatitis and liver failure following the use of a dietary supplement intended for weight loss or muscle building - may-october 2013. MMWR Morb Mortal Wkly Rep. 2013 Oct 11. 62(40):817-9. [Medline]. [Full Text].

  21. Hand L. CDC: supplement linked to hepatitis, liver failure. Medscape Medical News. October 15, 2013. Available at http://www.medscape.com/viewarticle/812581. Accessed: October 22, 2013.

  22. Lo Re V 3rd, Haynes K, Forde KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy's law and a new prognostic model. Clin Gastroenterol Hepatol. 2015 Dec. 13 (13):2360-8. [Medline].

  23. Klein AS, Hart J, Brems JJ, Goldstein L, Lewin K, Busuttil RW. Amanita poisoning: treatment and the role of liver transplantation. Am J Med. 1989 Feb. 86(2):187-93. [Medline].

  24. Hoyer DP, Munteanu M, Canbay A, et al. Liver transplantation for acute liver failure: are there thresholds not to be crossed?. Transpl Int. 2014 Jun. 27 (6):625-33. [Medline].

  25. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989 Aug. 97(2):439-45. [Medline].

  26. Lee WM, Galbraith RM, Watt GH, Hughes RD, McIntire DD, Hoffman BJ, et al. Predicting survival in fulminant hepatic failure using serum Gc protein concentrations. Hepatology. 1995 Jan. 21(1):101-5. [Medline].

  27. Schiødt FV, Rossaro L, Stravitz RT, Shakil AO, Chung RT, Lee WM. Gc-globulin and prognosis in acute liver failure. Liver Transpl. 2005 Oct. 11(10):1223-7. [Medline].

  28. [Guideline] Kelly JC. Drug-Induced Liver Injury Guidelines Released by ACG. Medscape Medical News. Jun 18 2014. [Full Text].

  29. [Guideline] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jun 17. [Medline].

  30. Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol. 1991 Jan. 12(1):1-9. [Medline].

  31. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004 Feb. 39(2):464-70. [Medline].

  32. Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis. 1996 Nov. 16(4):403-14. [Medline].

  33. Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2015 Dec 25. 1-20. [Medline].

  34. [Guideline] Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005 Jun. 41(6):1407-32. [Medline].

  35. AASLD position paper: the management of acute liver failure. Private Nonprofit Research Organization. American Association for the Study of Liver Diseases - Private Nonprofit Research Organization. 2005 May. 36(1):19 pages.

  36. ClinicalTrials.gov. The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure. Available at http://clinicaltrials.gov/ct2/show/NCT00655304.

  37. Fontana RJ, Ellerbe C, Durkalski VE, et al; for the US Acute Liver Failure Study Group. Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver Int. 2015 Feb. 35 (2):370-80. [Medline].

  38. Fairfield C, Penninga L, Powell J, Harrison EM, Wigmore SJ. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients. Cochrane Database Syst Rev. 2015 Dec 15. 12:CD007606. [Medline].

 
Previous
Next
 
Ultrasonogram shows a hyperechoic mass representing hepatocellular carcinoma.
Subacute subdural hematoma with extension into the anterior interhemispheric cistern. Note that the sutures do not contain the spread of these hemorrhages.
Table. Grading of Hepatic Encephalopathy
Grade Level of Consciousness Personality and Intellect Neurologic Signs Electroencephalogram (EEG) Abnormalities
0 Normal Normal None None
Subclinical Normal Normal Abnormalities only on psychometric testing None
1 Day/night sleep reversal, restlessness Forgetfulness, mild confusion, agitation, irritability Tremor, apraxia, incoordination, impaired handwriting Triphasic waves (5 Hz)
2 Lethargy, slowed responses Disorientation to time, loss of inhibition, inappropriate behavior Asterixis, dysarthria, ataxia, hypoactive reflexes Triphasic waves (5 Hz)
3 Somnolence, confusion Disorientation to place, aggressive behavior Asterixis, muscular rigidity, Babinski signs, hyperactive reflexes Triphasic waves (5 Hz)
4 Coma None Decerebration Delta/slow wave activity
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.